Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
The SidebySide Partnership is a London based Enterprise Investment Scheme (EIS) Venture Capital (VC) firm. Its purpose is to finance and control the management teams of its investee companies enabling them to become a developed corporate entity. The SidebySide Partnership's focus is on fast-growing technology businesses with £1 - 10 million in revenue. It provides 100% EIS relief on investment with zero initial/ongoing fees charged to investors. The SidebySide Partnership's investment experience of 20+ corporate acquisitions totalling more than $200 million, 20+ private investments, and a rate of interest of 12x over the last 35 years has enabled it to become a dependable platform for upcoming tech businesses. It will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£1,500,000
Lightpoint Medical is a technology company that is a pioneer in developing and marketing precision-guided cancer surgery. Surgeons aren't able to see if the cancerous tissue has been removed in its entirety or not during a surgery. To better this situation, the company has developed an imaging technology based on PET radiopharmaceuticals, more precisely, Cerenkov Luminescence Imaging (CLI), which helps surgeons to detect cancer in a real-time during surgery. The company's first product has received marketing authorisation, i.e., the CE (European Conformity) Mark. A second product, a laparoscopic device for prostate cancer is in development. A non-clinical device has also been released. For its efforts, Lightpoint Medical won the 'Best in Show' Award at the 2014 MedTech Investing Europe Conference. The company aims to utilise the investment to scale its business.
days to go:
Expired
investment:
Withheld
Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.
days to go:
Expired
investment:
£200,000
The world's first automated suturing tools for safe closure of standard and endoscopic wounds. Sutrue have already patented their devices and use industry-standard needles to offer clinical quality with improved speed and accuracy at the touch of a button. Needles are held in disposable cartridges as a safety feature to prevent injury when piercing skin with contaminated needles. This protects staff both during and after surgery for those working in medical and veterinary environments.
Sutrue is raising finance for the production process of their equipment, as well as applying for CE regulation via medical evaluations to receive approval to deploy their products in human and animal surgeries.
days to go:
Expired
investment:
Withheld
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go:
Expired
investment:
Withheld
Cyance is an award-winning marketing technology pioneer. Nexus is a software platform designed by the company to track the buying behaviour through billions of computers belonging to millions of businesses across the globe. This platform can track the consumed content and identifies customer interests and needs. The company's customers typically generate x3 more leads and x4 more sales. With the proceeds, Cyance will increase its marketing sales and improve product development to fund the general working capital.
days to go:
Expired
investment:
Withheld
Founded by entrepreneurs, Oliver Hutley (COO) and Rory Chichester (CEO), TECS Group is an expert provider of technology. TECS Group delivers non-discretionary critical services, such as Electrical Testing and Treatment, Gas Safety, and Fire Safety, on behalf of customers. These services are covered by strict legislation & regulation. Following a constant period of investment into developing a scalable and a solid operating platform, the TECS Group is embarking on its subsequent stage of growth. With the proceeds, the company will deliver and successfully implement its technology strategy, successfully drive for organic sales, increase the national coverage, and continue its final program.
days to go:
Expired
investment:
£96,770
FinOptix is an innovative FinTech company that solves real business problems. FinOptix’s objective is to become a significant player in a rapidly growing FinTech market by developing systems that provide financial clarity to decision-makers. FinOptix has a well-established user base, as well as a sales pipeline that covers multiple geographies and sectors. Their verification and validation procedures applied during the development process and operational trials have led to engagement with commercial partners. With the proceeds, they will design an Evaluator for the future, apply AI techniques to solve complex problems, develop their skill set and framework and hire a team of data scientists based on the assessment.
days to go:
Expired
investment:
£125,000
epaysecure is a secure payment system, which offers comprehensive payment and benefit options, and allows all the services the consumer demands to be offered in one card and e-account. The prepaid business purchasing in European markets is estimated to be $700 million. The company operates in an e-banking and financial services marketing sector that helps clients by identifying new markets and bringing in new ideas to develop them through reloadable products and e-Wallet platform. The funds will be used for staffing, set up costs, other overheads including property marketing and general office costs.
days to go:
Expired
investment:
£168,340
